Medical Cannabis for Endometriosis: Emerging Evidence and How to Access It

More than 1.5 million women in the United Kingdom are living with endometriosis — a chronic, often debilitating condition in which tissue similar to the uterine lining grows outside the womb. On average, they wait eight years for a diagnosis. For many, the years between symptom onset and confirmation are marked by dismissal, misdiagnosis and a succession of treatments that fail to provide adequate relief. Against this backdrop of systemic NHS failure, a growing number of UK women are turning to medical cannabis — and a small but accumulating body of evidence is beginning to justify their interest.

This article examines what the science currently shows, how women in England, Scotland and Wales are legally accessing cannabis-based medicines (CBMs) for endometriosis-related pain, and what the medical establishment is — cautiously — beginning to say.

Endometriosis and Pain: Why Conventional Treatments Fall Short

Endometriosis is classified as a chronic inflammatory disease. The ectopic lesions it produces respond to hormonal fluctuations across the menstrual cycle, causing cyclical — and often acyclical — pelvic pain, dysmenorrhoea (painful periods), dyspareunia (pain during intercourse), and in severe cases, bladder and bowel dysfunction. Approximately 10 per cent of women of reproductive age globally are affected; in the UK, the Endometriosis UK charity estimates the condition costs the economy £8.2 billion annually in healthcare, lost work and treatment.

First-line management typically begins with non-steroidal anti-inflammatory drugs (NSAIDs), combined oral contraceptives, or progestogens. When these fail — as they frequently do — patients may be offered GnRH analogues, which induce a medically temporary menopause, or laparoscopic excision surgery. NICE guideline NG73, updated in 2024, acknowledges that surgical excision reduces pain and improves quality of life in women with confirmed disease, but also notes that symptoms frequently recur. Many women undergo multiple surgeries over the course of their reproductive lives.

What conventional medicine has not solved is central sensitisation — the process by which prolonged nociceptive input remodels neural pathways so that pain persists independently of active lesions. It is here that the endocannabinoid system enters the picture.

The Endocannabinoid System and Endometrial Tissue: What Scientists Found

The endocannabinoid system (ECS) is a ubiquitous signalling network comprising endogenous ligands (primarily anandamide and 2-arachidonoylglycerol), the cannabinoid receptors CB1 and CB2, and the enzymes responsible for their synthesis and degradation. In healthy uterine tissue, the ECS regulates a range of processes including cell proliferation, immune response and pain modulation.

In 2017, Bouaziz and colleagues published what remains one of the foundational studies in this field. Examining endometrial stromal cells, the researchers demonstrated that endometriotic tissue expresses significantly reduced levels of N-acylethanolamine acid amidase (NAAA) — the enzyme responsible for degrading palmitoylethanolamide (PEA), an endogenous cannabinoid-like compound. Separately, CB1 receptor expression was found to be altered in women with endometriosis, with differential density in both eutopic and ectopic lesions compared with disease-free controls (Bouaziz et al., Journal of Molecular Endocrinology, 2017).

Dmitrieva and colleagues extended this work by examining spinal cord sensitisation in a rodent model of endometriosis. Their findings suggested that endocannabinoid tone influences both peripheral nociception at the lesion site and the central sensitisation pathways that perpetuate pain after lesions are removed — offering a mechanistic rationale for why some women with minimal visible disease report severe pain, and why surgical removal does not always confer lasting relief.

Crucially, CB2 receptors — expressed predominantly on immune cells — appear upregulated in endometriotic stromal cells. Given that endometriosis is now understood as an immune-mediated inflammatory condition, CB2 agonism offers a theoretically attractive target: modulating macrophage activity and reducing prostaglandin synthesis without the systemic side-effect profile of hormonal suppression.

Clinical Evidence: Can Cannabis Reduce Endometriosis Pain?

It would be dishonest to describe the clinical evidence base as robust. It is not — yet. The randomised controlled trial data that regulators and NICE require before issuing formal treatment recommendations does not currently exist for cannabis and endometriosis specifically. What exists is a growing constellation of observational studies, patient-reported outcomes surveys, and preclinical data that collectively build a plausible — if not yet definitive — case.

A widely-cited 2019 survey by Armour and colleagues, published in the Journal of Obstetrics and Gynaecology Canada, assessed self-management strategies among 484 women with endometriosis. Cannabis was rated the most effective self-management strategy for pain relief — above dietary change, heat application, and over-the-counter analgesia — by those who used it. Ninety-two per cent of cannabis users reported it reduced their pain; 83 per cent said it improved sleep; 59 per cent reported a reduction in pharmaceutical use.

These are patient-reported figures from a self-selected sample, and they come with all the methodological caveats that implies. The absence of a control group, the possibility of expectation bias, and the inability to control for cannabis type, dose or route of administration are significant limitations. The Endometriosis UK charity acknowledges growing patient interest but stops short of recommendation, calling for urgently needed clinical trials.

What clinicians are increasingly willing to do — within the framework of England’s post-2018 medical cannabis regime — is to consider cannabis-based medicines as part of an individualised pain management plan when conventional options have been exhausted. This is not a blanket endorsement; it is, in the language of specialist medicine, compassionate prescribing underpinned by biological plausibility.

CBD vs THC for Endometriosis Symptoms

CBD is non-intoxicating and acts primarily as an indirect modulator of the ECS rather than a direct CB1 or CB2 agonist. Its anti-inflammatory properties have been demonstrated in preclinical models; it inhibits the enzyme fatty acid amide hydrolase (FAAH), thereby raising endogenous anandamide levels. For women concerned about psychoactive effects — or those in occupations with drug-testing policies — CBD-dominant formulations represent the lower-risk starting point.

THC, by contrast, is a direct CB1 agonist with established analgesic properties. The analgesic evidence base for THC in chronic pain conditions is considerably stronger than for CBD in isolation — including data from multiple systematic reviews covering neuropathic pain, cancer pain and spasticity. Given that central sensitisation is a key feature of endometriosis-related pain, the CB1-mediated modulation of descending pain inhibition that THC enables may be particularly relevant. However, THC carries a dose-dependent risk of psychoactive side effects, cognitive impairment and, at high doses or with chronic use, cannabinoid hyperemesis and dependency risk.

In clinical practice, endometriosis patients in the UK are most commonly prescribed balanced THC:CBD oil formulations or THC-dominant flower for inhalation via a dry herb vaporiser — the latter offering rapid onset, which is particularly useful for acute dysmenorrhoea. Dosing is highly individualised and should always be titrated under specialist supervision.

Pelvic Pain, Dysmenorrhoea, Dyspareunia: Symptom-by-Symptom Evidence

Chronic pelvic pain is the symptom for which the biological rationale is strongest. CB1 receptors are expressed throughout the pelvic nerves and in dorsal root ganglia; preclinical models consistently demonstrate that cannabinoids reduce nociceptive signalling in these pathways. The Armour survey placed chronic pelvic pain among the symptoms most improved by cannabis use (mean reduction of 50% on a visual analogue scale among respondents).

Dysmenorrhoea — cyclical menstrual pain — is the most frequently reported endometriosis symptom. NSAIDs work by blocking prostaglandin synthesis; cannabinoids appear to inhibit prostaglandin E2 production via CB2 receptor activation and may additionally modulate uterine contractility. The combination of peripheral anti-inflammatory and central analgesic action makes cannabis pharmacologically plausible here, even if the trial evidence remains thin.

Dyspareunia — pain during or after intercourse — affects up to 70% of women with endometriosis and is among the most distressing symptoms, with well-documented impact on relationships and quality of life. There is very limited direct clinical data on cannabis specifically for dyspareunia in endometriosis. Some researchers have pointed to the presence of CB1 receptors in the vaginal wall and the potential role of the ECS in smooth muscle relaxation, but this remains theoretical.

Sleep disruption and mood — indirect but significant consequences of chronic pain — are areas where cannabis has a somewhat stronger evidence base. THC has been shown to reduce sleep onset latency and increase slow-wave sleep in short-term studies, though chronic use can suppress REM sleep.

Nausea and gastrointestinal symptoms associated with severe dysmenorrhoea or linked to bowel endometriosis may also respond to cannabis, given the well-established antiemetic and gut motility effects of cannabinoids — an area where clinical evidence, particularly for THC, is more established (including its licensed use in chemotherapy-induced nausea).

Symptom	Cannabis Evidence Rating	Standard NHS Alternatives
Chronic pelvic pain	Moderate (observational + preclinical)	NSAIDs, GnRH analogues, laparoscopy
Dysmenorrhoea	Low–Moderate (biologically plausible)	NSAIDs, COCPs, progestogens
Dyspareunia	Low (theoretical only)	Pelvic physiotherapy, surgery
Sleep disruption	Moderate (general pain insomnia data)	CBT-I, amitriptyline (off-label)
Nausea / GI symptoms	Moderate (antiemetic evidence base)	Antiemetics, bowel endometriosis surgery
Mood / anxiety	Low–Moderate (indirect; anxiety data mixed)	SSRIs (off-label), psychology referral

How UK Women Are Accessing Medical Cannabis for Endometriosis

Since November 2018, cannabis-based medicinal products (CBMPs) have been legal to prescribe in the United Kingdom for conditions where clinical need is established and conventional treatments have failed. The prescribing pathway requires a specialist — typically a consultant in pain medicine, gynaecology, neurology or psychiatry — to issue the prescription. General practitioners cannot prescribe CBMPs, though NHS England is currently piloting expanded access models.

In practice, the vast majority of medical cannabis prescriptions in the UK are issued through private specialist clinics. Organisations such as Releaf, Sapphire Medical, Alternaleaf and Rokeby Medical have established pathways specifically for complex pain conditions, and endometriosis increasingly appears on their patient registers. A typical first appointment involves a detailed pain history, a review of previous treatments and their outcomes, and — crucially — evidence that licensed alternatives have been tried and failed. This is not an open door; it is a filtered, clinically supervised process.

Costs remain a barrier. An initial specialist consultation typically costs £150–£300; ongoing prescriptions range from £150–£400 per month depending on the product and dose. There is no NHS reimbursement pathway for the vast majority of patients. Products are dispensed through licensed UK pharmacies with Schedule 2 controlled drug licences. For guidance on finding a prescribing specialist, see our Find a Doctor directory or read our full UK patient guide to medical cannabis access.

What Gynaecologists and Pain Clinics Are Saying

The medical establishment’s relationship with cannabis-based medicines for endometriosis is best described as cautious engagement rather than endorsement — or rejection. The Royal College of Obstetricians and Gynaecologists (RCOG) has not issued a specific position statement on CBMPs and endometriosis as of early 2026. NICE NG73 does not include cannabinoids in its treatment algorithm. However, the Faculty of Pain Medicine’s guidance on CBMPs acknowledges that certain patients with chronic pain — including neuropathic and centrally sensitised pain, both relevant to endometriosis — may derive benefit when prescribing is conducted by appropriately trained specialists within the existing regulatory framework.

Pain physicians working within multidisciplinary pelvic pain clinics are, informally, ahead of the published guidelines. Several UK consultants have spoken publicly — at the British Pain Society annual meetings and in specialist publications — about patients with complex endometriosis-related pain who have achieved meaningful improvements in pain scores, sleep and function following CBMP initiation, after years of treatment failure. These are anecdotes, not data. But they are informed anecdotes from clinicians who understand the limitations of what they are observing.

What the specialist community is consistent on: the need for properly designed, randomised controlled trials with endometriosis-specific endpoints. The absence of such trials is primarily a function of the regulatory complexity and funding environment surrounding cannabis research — not evidence of absence of effect. For clinicians seeking the evidence framework and product options relevant to their endometriosis patients, our For Clinicians hub provides formulary information and clinical liaison support.

Risks Specific to Women of Reproductive Age

Fertility: Preclinical evidence suggests the ECS plays a regulatory role in folliculogenesis, fertilisation, implantation and early pregnancy. Several epidemiological studies have associated cannabis use with altered ovarian reserve markers and disrupted luteal phase function. Women attempting to conceive should not initiate CBMP therapy without a detailed discussion of this risk — and most responsible prescribers would pause or discontinue treatment during any conception attempt or confirmed pregnancy.

Pregnancy: There is no established safe level of cannabis use in pregnancy. THC crosses the placental barrier. Associations with low birth weight, preterm delivery and longer-term neurodevelopmental differences have been reported in observational data. Medical cannabis is contraindicated in pregnancy.

Breastfeeding: THC is detectable in breast milk; its effects on infant neurodevelopment are not fully characterised. Medical cannabis is not recommended during breastfeeding.

Psychiatric risk: High-THC formulations carry a dose-dependent risk of anxiety, paranoia and — in genetically susceptible individuals — psychosis. Women with personal or family history of psychotic illness, bipolar disorder or severe anxiety disorder require careful risk stratification before initiation.

Dependency: Cannabis use disorder affects approximately 9% of users who initiate use in adulthood. In a chronic pain context, dependency risk warrants monitoring and should be discussed at outset. For a comprehensive risk-benefit overview, see our clinical resource on medical cannabis and chronic pain.

The Path Forward

The scientific interest in medical cannabis for endometriosis is genuine, biologically grounded and growing. The clinical evidence, however, remains insufficient to support guideline-level recommendations. That gap — between biological plausibility and clinical proof — is where most patients currently exist: making difficult decisions under uncertainty, with inadequate NHS support and variable access to informed specialist guidance.

What would change the picture is straightforward, if not easy to deliver: adequately powered, randomised trials with standardised CBMP formulations and endometriosis-specific endpoints. The Endometriosis UK charity has repeatedly called for this research; the academic infrastructure in the UK — through institutions including Imperial College London’s Centre for Endometriosis — is capable of delivering it. Funding and regulatory coordination remain the constraints.

In the interim, women with treatment-refractory endometriosis pain in the UK can legally access cannabis-based medicines through a licensed specialist prescriber. The eight-year diagnosis delay that defines the endometriosis patient experience in the UK is a systemic failure. Medical cannabis is not a cure, and it is not yet a proven treatment. But it is a legal, clinically supervised option that a growing number of women are finding reduces their burden — and one that the science suggests is worth taking seriously.

---

Medically reviewed by the Cannamedical Britannia Clinical Team, May 2026. This article is for informational purposes only and does not constitute medical advice. Consult a qualified specialist before initiating or changing any treatment.

Key sources: Bouaziz et al., Journal of Molecular Endocrinology (2017); Dmitrieva N et al., Neuroscience; Armour M et al., JOGC (2019); NICE Guideline NG73 (updated 2024); Endometriosis UK charity position statements; Faculty of Pain Medicine CBMP guidance (2019).